+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Challenges and opportunities for new protein crystallization strategies in structure-based drug design



Challenges and opportunities for new protein crystallization strategies in structure-based drug design



Expert Opinion on Drug Discovery 5(11): 1039-1045



Structure-based drug design (SBDD) has emerged as a valuable pharmaceutical lead discovery tool, showing potential for accelerating the discovery process,while reducing developmental costs and boosting potencies of the drug that is ultimately selected. SBDD is an iterative, rational, lead compound sculpting process that involves both the synthesis of new derivatives and the evaluation of their binding to the target structure either through computational docking or elucidation of the target structure as a complex with the lead compound. This method heavily relies on the production of high resolution(< 2 Å) 3D structures of the drug target, obtained through X-ray crystallographic analysis, in the presence or absence of the drug candidate.The lack of generalized methods for high quality crystal production is still a major bottleneck in the process of macromolecular crystallization. This review provides a brief introduction to SBDD and describes several macromolecular crystallization strategies, with an emphasis on advances and challenges facing researchers in the field today. Recent trends in the development of more universal macromolecular crystallization techniques, particularly nucleation-based techniques that are applicable to both soluble and integral membrane proteins, are also discussed.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 052001592

Download citation: RISBibTeXText

PMID: 21116481

DOI: 10.1517/17460441.2010.515583


Related references

Structure-based drug design to overcome drug resistance: challenges and opportunities. Current Pharmaceutical Design 20(5): 687-693, 2014

Structure-based drug design: strategies and challenges. Current Pharmaceutical Design 20(5): 685-686, 2014

Structure-Based Drug Design Strategies and Challenges. Current Topics in Medicinal Chemistry 18(12): 998, 2018

Protein crystallization for structure-based drug design. Methods in Molecular Biology 841: 67-91, 2012

Challenges, applications, and recent advances of protein-ligand docking in structure-based drug design. Molecules 19(7): 10150-10176, 2014

Drug Delivery to CNS: Challenges and Opportunities with Emphasis on Biomaterials Based Drug Delivery Strategies. Current Pharmaceutical Design 22(19): 2913-2922, 2016

Exploration of structure-based drug design opportunities for mGluRs. Neuropharmacology 60(1): 93, 2011

Urban Design and Civil Society in New Orleans: Challenges, Opportunities and Strategies in the Post-Flood Design Moment. Journal of Urban Design 14(3): 309-324, 2009

Crystallization to obtain protein-ligand complexes for structure-aided drug design. Acta Crystallographica. Section D Biological Crystallography 62(Pt 6): 569-575, 2006

Enabling structure-based drug design of Tyk2 through co-crystallization with a stabilizing aminoindazole inhibitor. Bmc Structural Biology 12: 22, 2012

Current and emerging opportunities for molecular simulations in structure-based drug design. Physical Chemistry Chemical Physics 16(10): 4465-4477, 2014

Structure-based drug design: progress, results and challenges. Structure 2(7): 577-587, 1994

Engineering of an isolated p110α subunit of PI3Kα permits crystallization and provides a platform for structure-based drug design. Protein Science 23(10): 1332-1340, 2014

Structure-based strategies for drug design and discovery. Science 257(5073): 1078-1082, 1992

The impact of crystallization conditions on structure-based drug design: A case study on the methylene blue/acetylcholinesterase complex. Protein Science 25(6): 1096-1114, 2016